- China
- /
- Healthcare Services
- /
- SZSE:301015
Top Chinese Dividend Stocks For August 2024
Reviewed by Simply Wall St
As of August 2024, Chinese equities have shown mixed performance amid weak manufacturing data and tempered investor sentiment. The Shanghai Composite Index saw a modest gain, while the CSI 300 and Hang Seng Index experienced slight declines. In this context, dividend stocks can offer a stable income stream and potential for capital appreciation. Here are three top Chinese dividend stocks to consider for August 2024.
Top 10 Dividend Stocks In China
Name | Dividend Yield | Dividend Rating |
Midea Group (SZSE:000333) | 5.01% | ★★★★★★ |
Changhong Meiling (SZSE:000521) | 3.56% | ★★★★★★ |
Wuliangye YibinLtd (SZSE:000858) | 3.71% | ★★★★★★ |
Ping An Bank (SZSE:000001) | 7.24% | ★★★★★★ |
Inner Mongolia Yili Industrial Group (SHSE:600887) | 4.94% | ★★★★★★ |
China South Publishing & Media Group (SHSE:601098) | 4.72% | ★★★★★★ |
Huangshan NovelLtd (SZSE:002014) | 5.99% | ★★★★★★ |
HUAYU Automotive Systems (SHSE:600741) | 5.00% | ★★★★★★ |
Chacha Food Company (SZSE:002557) | 3.66% | ★★★★★★ |
Zhejiang Jiaxin SilkLtd (SZSE:002404) | 5.58% | ★★★★★★ |
Click here to see the full list of 260 stocks from our Top Chinese Dividend Stocks screener.
Here's a peek at a few of the choices from the screener.
Shan Xi Hua Yang Group New EnergyLtd (SHSE:600348)
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Shan Xi Hua Yang Group New Energy Ltd (SHSE:600348) is engaged in the production and distribution of new energy products, with a market cap of CN¥26.30 billion.
Operations: Shan Xi Hua Yang Group New Energy Ltd (SHSE:600348) generates revenue primarily from the production and distribution of new energy products.
Dividend Yield: 9.8%
Shan Xi Hua Yang Group New Energy Ltd. offers a high dividend yield of 9.85%, placing it in the top 25% of dividend payers in China. However, its dividends have been volatile over the past decade and are not well covered by free cash flows or earnings, raising sustainability concerns. The company trades at a favorable P/E ratio of 6.2x compared to the market average of 27.5x, suggesting good relative value despite inconsistent dividend reliability.
- Dive into the specifics of Shan Xi Hua Yang Group New EnergyLtd here with our thorough dividend report.
- Our comprehensive valuation report raises the possibility that Shan Xi Hua Yang Group New EnergyLtd is priced lower than what may be justified by its financials.
Chacha Food Company (SZSE:002557)
Simply Wall St Dividend Rating: ★★★★★★
Overview: Chacha Food Company, Limited produces and sells fresh nuts in China with a market cap of CN¥13.73 billion.
Operations: Chacha Food Company, Limited generates CN¥7.29 billion in revenue from its Leisure Food segment.
Dividend Yield: 3.7%
Chacha Food Company offers a reliable dividend yield of 3.66%, placing it in the top 25% of CN market dividend payers. The dividends are well-covered by earnings (58.8% payout ratio) and cash flows (48% cash payout ratio). Over the past decade, dividends have been stable and growing. Recently, Chacha completed a significant share buyback program worth CNY 99.99 million, enhancing shareholder value further through equity incentive plans or employee stock ownership plans.
- Delve into the full analysis dividend report here for a deeper understanding of Chacha Food Company.
- Insights from our recent valuation report point to the potential undervaluation of Chacha Food Company shares in the market.
Qingdao Baheal Medical (SZSE:301015)
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Qingdao Baheal Medical INC. focuses on the research, development, production, and sale of pharmaceutical products and has a market cap of CN¥12.29 billion.
Operations: Qingdao Baheal Medical INC.'s revenue segments include research and development, production, and sale of pharmaceutical products.
Dividend Yield: 3.3%
Qingdao Baheal Medical trades at 75.4% below its estimated fair value, offering a dividend yield of 3.26%, among the top 25% in the CN market. Dividends are covered by earnings (61.2% payout ratio) and cash flows (83.4% cash payout ratio). Although dividends have been stable and growing, they have only been paid for two years. Recent events include a final profit distribution plan and an extraordinary shareholders meeting to discuss acquisitions in four companies.
- Click here and access our complete dividend analysis report to understand the dynamics of Qingdao Baheal Medical.
- Our valuation report here indicates Qingdao Baheal Medical may be undervalued.
Taking Advantage
- Navigate through the entire inventory of 260 Top Chinese Dividend Stocks here.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Qingdao Baheal Medical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:301015
Qingdao Baheal Medical
Engages in research and development, production, and sale of pharmaceutical products.
Outstanding track record with flawless balance sheet and pays a dividend.